Chicago IL 乳腺癌临床试验
59项针对 乳腺癌的研究正在 Chicago及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
招募中1/2 期
- Research Site, Chicago
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
招募中3 期
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
A Study of PHST001 in Advanced Solid Tumors
招募中1 期
- University of Chicago Medical Center, Chicago
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
招募中3 期
- Affiliated Oncologists IL, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 以及另外 1 项
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- University of Illinois Cancer Center, Chicago
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
招募中2 期
- University of Illinois Cancer Center, Chicago
- The University of Chicago, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
招募中1/2 期
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
招募中
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
招募中3 期
- Rush University Medical Center ( Site 0079), Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Chicago
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
招募中
- Northwestern University, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
招募中欢迎健康志愿者
- University of Chicago, Chicago
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
招募中1/2 期
- University of Illinois Hospital & Health Sciences System, Chicago
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- Northwestern Memorial Hospital, Chicago
- RUSH MD Anderson Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- University of Chicago, Chicago
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
招募中1/2 期
- Northwestern University, Chicago
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
招募中2 期
- Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago, Chicago
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
招募中2 期
- University of Illinois Cancer Center, Chicago
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
招募中3 期
- Northwestern University, Chicago
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- 以及另外 4 项
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
招募中欢迎健康志愿者
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
招募中2 期
- University of Chicago Medical Center, Chicago
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
招募中2 期
- University of Illinois, Chicago
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
招募中2 期
- Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
ATEMPT 2.0: Adjuvant T-DM1 vs TH
招募中2 期
- The University of Chicago Medical Center, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
招募中3 期
- Northwestern University, Chicago
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Local Institution - 0280, Chicago
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
招募中3 期
- Northwestern University - Northwestern Memorial Hospital, Chicago
E-Mindfulness Approaches for Living After Breast Cancer
招募中3 期
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
招募中2 期
- Northwestern University, Chicago
- University of Illinois College of Medicine - Chicago, Chicago
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
招募中4 期
- University of Illinois, Chicago
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
招募中2 期
- Northwestern University, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Northwestern University, Chicago
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
招募中2 期
- University of Illinois Cancer Center, Chicago
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
招募中1 期
- University of Chicago Comprehensive Cancer Center, Chicago
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- University of Chicago, Chicago
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
招募中2 期
- Northwestern University, Chicago
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
招募中
- Robert H. Lurie Comprehensive Cancer Center, Chicago
- University of Illinois Chicago, Chicago
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
招募中2 期
- University of Chicago Medical Center, Chicago
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- Rush MD Anderson Cancer Center, Chicago
- 以及另外 2 项
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
招募中1 期
- Northwestern Memorial Hospital, Chicago
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
招募中2 期
- University of Chicago, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- University of Chicago Medical Center, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中观察性研究
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
招募中
- University of Illinois, Chicago
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
招募中2 期
- University of Chicago Medical Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
招募中1 期
- The University of Chicago Comprehensive Cancer Center, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
招募中4 期
- University of Chicago Medical Center, Chicago
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
招募中观察性研究
- Rush Cancer Center, Chicago
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
招募中2 期
- University of Illinois, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Chicago
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
招募中观察性研究
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
招募中3 期
- John H Stroger Jr Hospital of Cook County, Chicago
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
招募中1 期
- University of Chicago Medical Center, Chicago
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
招募中观察性研究
- University of Illinois at Chicago, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
招募中观察性研究欢迎健康志愿者
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
其他城市的 乳腺癌试验
- New York City, NY136 项研究
- Houston, TX126 项研究
- Boston, MA112 项研究
- Nashville, TN81 项研究
- Los Angeles, CA73 项研究
- Edison, NJ68 项研究
- St. Louis, MO64 项研究
- Queens, NY64 项研究
- Durham, NC64 项研究
- Philadelphia, PA56 项研究
- Dallas, TX55 项研究
- San Antonio, TX47 项研究
Chicago的其他研究
- 非小细胞肺癌61 项研究
- 癌症（所有类型）51 项研究
- 转移性癌症45 项研究
- 前列腺癌45 项研究
- 肺癌41 项研究
- 肥胖症41 项研究
- 卵巢癌36 项研究
- 结直肠癌34 项研究
- 卒中34 项研究
- 心力衰竭31 项研究
- 超重29 项研究
- 头颈鳞状细胞癌26 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。